Sanofi Pasteur (JOBS) Purchases Rights to Syntiron LLC's MRSA Vaccine; Sanofi Will Pay Syntiron Upfront Fee, Research Capital, and Several Milestone Payments That Could Reach $149 Million

Published: Dec 16, 2009

Bookmark and Share

Bloomberg -- Sanofi-Aventis SA bought rights to a vaccine designed to prevent infection with Staphylococcus bacteria from closely held U.S. biotechnology company Syntiron.

Back to news